Pseudoprogression after glioma therapy: a comprehensive review. (April 2013)

• Record Type: Journal Article
• Authors: Kruser, Tim J; Mehta, Minesh P; Robins, H Ian
• Is Part Of: Expert review of neurotherapeutics. Volume 13:Number 4(2013)
• Page Start: 389
• Page End: 403
• Publication Date: 2013-04
• Subjects: glioblastoma -- pseudoprogression -- radiation necrosis -- temozolomide; Neuropharmacology -- Periodicals; 615.7805
• DOI: 10.1586/ern.13.7
• Languages: English
• ISSNs: 1473-7175

Abstract

Over the last decade, pseudoprogression as a clinically significant entity affecting both glioma patient management and the conduct of clinical trials has been recognized as a significant issue. The authors have summarized the literature relative to the incidence, chronological sequence, therapy-relatedness, impact of O -6-methylguanine-DNA methyltransferase methylation status and clinical features of pseudoprogression. Evidence regarding numerous neuroradiologic techniques to differentiate pseudoprogression from tumor recurrence is summarized. The implications of pseudoprogression on prognosis and clinical trial design are substantial, and are reviewed. Relative to this, the overlapping terms pseudoprogression and radiation necrosis are clarified to produce an appropriate basis for future consideration and research regarding this important biological phenomenon.